83 related articles for article (PubMed ID: 647694)
1. Combination chemotherapy: arriving at optimal treatment levels by incorporating side effect constraints.
Wampler GL; Carter WH; Williams VR
Cancer Treat Rep; 1978 Mar; 62(3):333-40. PubMed ID: 647694
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia.
Grossie VB; Rosenblum MG; Loo TL
Cancer Treat Rep; 1982 Aug; 66(8):1631-4. PubMed ID: 6809329
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
4. An improved method for analyzing survival data from combination chemotherapy experiments.
Carter WH; Stablein DM; Wampler GL
Cancer Res; 1979 Sep; 39(9):3446-53. PubMed ID: 476674
[TBL] [Abstract][Full Text] [Related]
5. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Avery TL; Roberts D
Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy of L1210 leukemia with Damvar and cytostatics.
Pujman V; Cernochová S
Neoplasma; 1979; 26(5):521-3. PubMed ID: 522924
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
Gale GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
Cancer Treat Rep; 1977; 61(3):445-50. PubMed ID: 872142
[TBL] [Abstract][Full Text] [Related]
8. Single versus combination chemotherapy of L1210 leukemia.
Koza I; Balázová E; Ujházy V
Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
10. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.
Wampler GL; Carter WH; Campbell ED; Goldman ID
Cancer Treat Rep; 1987 Jun; 71(6):581-91. PubMed ID: 3581096
[TBL] [Abstract][Full Text] [Related]
12. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
[TBL] [Abstract][Full Text] [Related]
13. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide.
Scheving LE; Burns ER; Pauly JE; Halberg F
Cancer Res; 1980 May; 40(5):1511-5. PubMed ID: 7370988
[No Abstract] [Full Text] [Related]
14. Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
Stoychkov JN; Milushev AS; Todorov DK
Neoplasma; 1980; 27(1):33-6. PubMed ID: 6892839
[TBL] [Abstract][Full Text] [Related]
15. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue.
Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV
Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402
[TBL] [Abstract][Full Text] [Related]
17. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
18. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
[TBL] [Abstract][Full Text] [Related]
19. On determining the levels of treatment to optimize the probability of a favorable response.
Carter WH; Wampler GL; Crews SL; Howells R
Cancer Treat Rep; 1977 Aug; 61(5):849-53. PubMed ID: 408002
[TBL] [Abstract][Full Text] [Related]
20. Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation.
Pouillart R; Huong TH; Brugerie E; Lheritier J
Biomedicine; 1974 Dec; 21(12):471-9. PubMed ID: 4462870
[No Abstract] [Full Text] [Related]
[Next] [New Search]
